Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury

Sun, Shifei; Sun, Shibin; Meng, Yan; Shi, Bin; Chen, Yuanzhen

doi:10.1155/2021/4549049

Cited by 8 publications

(8 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The determination of Netrin-1 adopts enzyme-linked immunosorbent assay (ELISA) method, and the antibody adopts commercial product. The specific ELISA steps refer to the instructions and previous reports [ 18 , 19 ].…”

Section: Methodsmentioning

confidence: 99%

Netrin-1: A Serum Marker Predicting Cognitive Impairment after Spinal Cord Injury

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objective. Although cognitive impairment has received more attention in recent years as a result of spinal cord injury (SCI), the pathogenic process that causes it is still unknown. The neuroprotective effects of Netrin as a family of laminin-related secreted proteins were discovered. The purpose of this study was to determine the changes of serum Netrin-1 after SCI and its relationship with cognitive impairment. Methods. 96 SCI patients and 60 controls were included in our study. We collected baseline data from all participants, measured their serum Netrin-1 levels, and followed up their cognitive levels 3 months later. Results. The clinical baseline values between the control and SCI groups were not significantly different ( p > 0.05 ). However, the serum Netrin-1 level in the SCI group was significantly lower than that in the control group ( 528.4 ± 88.3 pg/ml vs. 673.5 ± 97.2 pg/ml, p < 0.05 ). According to the quartile level of serum Netrin-1 level in the SCI group, we found that with the increase of serum Netrin-1 level, the MoCA score also increased significantly ( p < 0.001 ), indicating that the serum Netrin-1 level was positively correlated with the MoCA score after SCI. After controlling for baseline data, multiple regression analysis revealed that Netrin-1 remained an independent risk factor for cognitive impairment after SCI (=0.274, p = 0.036 ). Conclusions. Netrin-1 may be a neuroprotective factor for cognitive impairment, which may serve as a serum marker to predict cognitive impairment after SCI.

show abstract

Section: Methodsmentioning

confidence: 99%

Netrin-1: A Serum Marker Predicting Cognitive Impairment after Spinal Cord Injury

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, studies have demonstrated a relationship between systemic blood pressure and blood flow velocity and cognitive impairment following SCI ( Wecht et al, 2018 ). Our earlier research has demonstrated that neurogenesis, oxidative stress, and inflammation contribute to cognitive impairment following SCI ( Liu et al, 2022 ; Sun et al, 2021 ; Chen et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury

Cui

Wang

Hao

et al. 2023

PeerJ

Self Cite

View full text Add to dashboard Cite

Objective Recent studies have suggested that high levels of β2-microglobulin are linked to cognitive deterioration; however, it is unclear how this connects to spinal cord injury (SCI). This study sought to determine whether there was any association between cognitive decline and serum β2-microglobulin levels in patients with SCI. Methods A total of 96 patients with SCI and 56 healthy volunteers were enrolled as study participants. At the time of enrollment, specific baseline data including age, gender, triglycerides (TG), low-density lipoprotein (LDL), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), smoking, and alcohol use were recorded. Each participant was assessed by a qualified physician using the Montreal cognitive assessment (MoCA) scale. Serum β2-microglobulin levels were measured using an enzyme-linked immunosorbent assay (ELISA) reagent for β2-microglobulin. Results A total of 152 participants were enrolled, with 56 in the control group and 96 in the SCI group. There were no significant baseline data differences between the two groups (p > 0.05). The control group had a MoCA score of 27.4 ± 1.1 and the SCI group had a score of 24.3 ± 1.5, with the difference being significant (p < 0.05). The serum ELISA results revealed that the levels of β2-microglobulin in the SCI group were considerably higher (p < 0.05) than those in the control group (2.08 ± 0.17 g/mL compared to 1.57 ± 0.11 g/mL). The serum β2-microglobulin level was used to categorize the patients with SCI into four groups. As serum β2-microglobulin levels increased, the MoCA score reduced (p < 0.05). After adjustment of baseline data, further regression analysis showed that serum β2-microglobulin level remained an independent risk factor for post-SCI cognitive impairment. Conclusions Patients with SCI had higher serum levels of β2-microglobulin, which may be a biomarker for cognitive decline following SCI.

show abstract

“…Additionally, the NPAF has a stimulatory effect on memory consolidation in passive avoidance learning [ 228 ]. Serum NPFF levels are significantly elevated in patients with spinal cord injury [ 229 ], which is associated with cognitive impairment [ 230 ]. These data suggest that the NPFF may have prognostic value for predicting cognitive impairment in patients with spinal cord injury, as its peripheral levels are normally limited and could arise due to leakage from CNS tissues [ 231 ].…”

Section: Anorexigenic Neuropeptidesmentioning

confidence: 99%

Anorexigenic neuropeptides as anti-obesity and neuroprotective agents

Strnadová,

Pačesová,

Charvát

et al. 2024

Bioscience Reports

View full text Add to dashboard Cite

Since 1975, the incidence of obesity has increased to epidemic proportions, and the number of patients with obesity has quadrupled. Obesity is a major risk factor for developing other serious diseases, such as type 2 diabetes mellitus, hypertension, and cardiovascular diseases. Recent epidemiologic studies have defined obesity as a risk factor for the development of neurodegenerative diseases, such as Alzheimer's disease (AD) and other types of dementia. Despite all these serious comorbidities associated with obesity, there is still a lack of effective antiobesity treatment. Promising candidates for the treatment of obesity are anorexigenic neuropeptides, which are peptides produced by neurons in brain areas implicated in food intake regulation, such as the hypothalamus or the brainstem. These peptides efficiently reduce food intake and body weight. Moreover, because of the proven interconnection between obesity and the risk of developing AD, the potential neuroprotective effects of these two agents in animal models of neurodegeneration have been examined. The objective of this review was to explore anorexigenic neuropeptides produced and acting within the brain, emphasizing their potential not only for the treatment of obesity but also for the treatment of neurodegenerative disorders.

show abstract

Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury

Cited by 8 publications

References 61 publications

Netrin-1: A Serum Marker Predicting Cognitive Impairment after Spinal Cord Injury

Netrin-1: A Serum Marker Predicting Cognitive Impairment after Spinal Cord Injury

Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury

Anorexigenic neuropeptides as anti-obesity and neuroprotective agents

Contact Info

Product

Resources

About